Abbott wins CE mark for dual glucose-ketone sensor
May 27, 2026
Abbott (NYSE:ABT) announced today that it received CE mark approval for its dual glucose-ketone sensing technology for people with diabetes.
Abbott (NYSE:ABT) announced today that it received CE mark approval for its dual glucose-ketone sensing technology for people with diabetes.
Engineers at the University of California San Diego have created a soft, wearable ultrasound patch that can continuously monitor a fetus for hours at a time—and it can do so consistently even as the fetus and umbilical cord constantly move during pregnancy.
Researchers at Umeå University have conducted a unique three-dimensional mapping of an entire human pancreas. The study shows that insulin-producing cells can remain long after the onset of type 1 diabetes—a finding that suggests the disease progression is more complex than previously assumed.
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the TOBY Alzheimer’s Test, a urine-based diagnostic test developed by TOBY, a biotechnology company based in Austin, Texas.
The CE certification confirms compliance with regulatory standards for safety, efficacy, and quality management.
Neurovalens announced today that it received FDA de novo approval for Modius Spero, a post-traumatic stress disorder (PTSD) therapy.
Researchers from the National University of Singapore (NUS) have developed an AI-guided workflow that combines artificial intelligence (AI) with molecular simulations to identify potential drug candidates for diabetic wound healing, identifying folic acid, a common vitamin, as a top candidate.
Detecting melanoma before it becomes visible is a major challenge in dermatology. Now, with researchers from Université de Montréal, scientists at Université du Québec’s Institut national de la recherche scientifique (INRS) have developed a promising solution.
Cornerstone Robotics announced today that it received CE mark approval for its Sentire endoscopic surgical robotic platform.
In a study published in Nature Communications, the researchers found that the EXO1 gene is overexpressed in 20% to 30% of breast and ovarian cancers as well as in melanoma, testicular, cervical, and hepatobiliary cancers, which develop in the liver, gall bladder, and bile duct